GCP
JSPR icon

GSA Capital Partners’s Jasper Therapeutics JSPR Stock Holding History

GSA Capital Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Sell
19,084
-55,880
-75% -$77.6K ﹤0.01% 1647
2025
Q4 		$137K Buy
+74,964
New +$150K 0.01% 1491

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

GSA Capital Partners's JSPR Position: Q1 2026 in Review

GSA Capital Partners reduced its Jasper Therapeutics (JSPR) stake by 75% in Q1 2026, selling an estimated $77.6K and leaving 19,084 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

GSA Capital Partners first reported a position in JSPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $137K in Q4 2025. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • GSA Capital Partners held 19,084 shares of Jasper Therapeutics worth $17K as of Q1 2026.
  • GSA Capital Partners sold 55,880 Jasper Therapeutics shares in Q1 2026, an estimated $77.6K.
  • Jasper Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q1 2026, its #1647 holding.
  • GSA Capital Partners first reported a position in Jasper Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • GSA Capital Partners's Jasper Therapeutics position peaked at $137K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.